Plus therapeutics provides us launch update for its cnside® diagnostic

Cnside available for the state of texas in august 2025 initial commercial focus on nci-designated cancer centers and large private healthcare systems company will expand testing services and broaden regional availability over the next 12 months houston, july 31, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, announces that its wholly-owned subsidiary, cnside diagnostics, llc (“cnside”) will make cnside cerebrospinal fluid (csf) assay platform and testing services commercially available in texas in august 2025. initial commercial focus will be on national cancer institute (nci) designated cancer centers, which treat the highest number of patients at risk for leptomeningeal metastases (lm) and previously used cnside.
PSTV Ratings Summary
PSTV Quant Ranking